Association between nutritional screening via the Controlling Nutritional Status index and bone mineral density in chronic liver disease of various etiologies

Hepatology Research

Volumn 45, Issue 6, 2015, Pages 618-628

  López Larramona, Germán ^a   Lucendo, Alfredo J ^a   Tenías, José María ^b  

^a Vereda de Socuéllamos s n   (Spain)

^b Castilla La Mancha Health Service   (Spain)

Author keywords

Bone mineral density; Chronic liver disease; Cirrhosis; Controlling Nutritional Status index; Nutritional status; Osteoporosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIFEDIOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; SPIRONOLACTONE; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; AUTOIMMUNE HEPATITIS; BONE DENSITY; BONE METABOLISM; CHOLESTEROL BLOOD LEVEL; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; CHRONIC LIVER DISEASE; CONTROLLED STUDY; CONTROLLING NUTRITIONAL STATUS INDEX; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DESCRIPTIVE RESEARCH; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; HEMOCHROMATOSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIVER CIRRHOSIS; LIVER FUNCTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUTRITIONAL ASSESSMENT; NUTRITIONAL STATUS; OSTEOPENIA; OSTEOPOROSIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; WILSON DISEASE; WORLD HEALTH ORGANIZATION;

EID: 84930274376     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12395     Document Type: Article

References (71)

1. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts and prospects. J Clin Invest 2005; 115: 3318-3325.
2. Conchillo M, Prieto J, Quiroga J. Insulin-like growth factor I (IGF-I) and liver cirrhosis. Rev Esp Enferm Dig 2007; 99: 156-164.
3. Leslie WD, Bernstein CN, Leboff MS, American Gastroenterological Association Clinical Practice Committee. AGA Technical review on osteoporosis in hepatic disorders. Gastroenterology 2003; 125: 941-966.
4. Report of WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser 1994; 843: 1-129.
5. Hay JE, Guichelaar MMJ. Evaluation and management of osteoporosis in liver disease. Clin Liver Dis 2005; 9: 747-766.
6. Guañabens N, Pares A. Liver and bone. Arch Biochem Biophys 2010; 503: 84-94.
7. Mahmoudi A, Sellier N, Reboul-Marty J etal. Bone mineral density assessed by dual-energy X-ray absorptiometry in patients with viral or alcoholic compensated cirrhosis. A prospective study. Clin Res Hepatol Gastroenterol 2011; 35: 731-737.
8. Wariaghli G, Mounach A, Achemlal L etal. Osteoporosis in chronic liver disease: a case-control study. Rheumatol Int 2010; 30: 893-899.
9. Guichelaar MMJ, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl 2005; 12: 1390-1402.
10. Menon K, Angulo P, Weston S, Dickson ER, Lindor K. Bone disease in primary biliary cirrhosis:independent indicators and rate of progression. J Hepatol 2001; 35: 316-323.
11. Guañabens N, Parés A. Osteoporosis in liver cirrhosis. Gastroenterol Hepatol 2012; 35: 411-420.
12. Nakchbandi S, van der Merwe SW. Current understanding of osteoporosis associated with liver disease. Nat Rev Gastroenterol Hepatol 2009; 6: 660-670.
13. Yadav A, Carey EJ. Osteoporosis in chronic liver disease. Nutr Clin Pract 2013; 28 (1): 52-64.
14. Kondrup J. Nutrition in end stage liver disease. Best Pract Res Clin Gastroenterol 2006; 20: 547-560.
15. Plauth M, Cabré E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J. ESPEN Guidelines on enteral nutrition: liver disease. Clin Nutr 2006; 2: 285-294.
16. Taniguchi E, Kawaguchi T, Otsuka M etal. Nutritional assessments for ordinary medical care in patients with chronic liver disease. Hepatol Res 2013; 43: 192-199.
17. de Ulíbarri JI, González-Madroño A, de Villar GP etal. CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp 2005; 1: 38-45.
18. Monegal A, Navasa M, Guañabens N etal. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 1997; 60: 148-154.
19. Pares A, Guañabens N, Ros I, Caballeria L, Pons F, Vidal S. Duration and severity of the disease but not menopausal status are the main risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 2002; 36: 154-155.
20. Diamond T, Stiel D, Lunzer M, Wilkinson M, Roche J, Posen S. Osteoporosis and skeletal fractures in chronic liver disease. Gut 1990; 31: 82-87.
21. Sokhi RP, Anantharaju A, Kondaveeti R, Creech SD, Islam KK, van Thiel D. Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transpl 2004; 10: 648-653.
22. Guggenbuhl P, Deugnier Y, Boisdet JF etal. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int 2005; 16: 1809-1814.
23. Gonzalez-Calvin JL, Mundi JL, Casado-Caballero FJ, Abadia AC, Martin-Ibañez JJ. bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis. J Clin Metab 2009; 94: 4844-4850.
24. Guañabens N, Pares A, Marinosos L. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 1990; 85: 1356-1362.
25. Guichelaar MM, Malinchoc M, Sibonga JD, Clarke BL, Hay JE. Bone histomorphometric changes after liver transplantation for chronic cholestatic liver disease. J Bone Miner Res 2003; 18: 2190-2199.
26. Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998; 28: 695-699.
27. Ruiz-Gaspà S, Martínez-Ferrer A, Guañabens N etal. Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseases. Hepatology 2011; 54: 2104-2113.
28. Peris P, Parès A, Guañabens N etal. Reduced spinal and femoral bone mass and deranged bone mineral metabolism in chronic alcoholics. Alcohol Alcohol 1992; 27: 619-625.
29. Guañabens N, Cerdá D, Monegal A etal. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology 2010; 138: 2348-2356.
30. Cuthbert JA, Pak CY, Zerwekh JE, Glass KD, Combes B. Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia. Hepatology 1984; 4: 1-8.
31. Hodgson SF, Dickson ER, Eastell R, Eriksen EF, Bryant SC, Riggs BL. Rates of cancellous bone remodelling and turnover in osteopenia associated with primary biliary cirrhosis. Bone 1993; 14: 819-827.
32. Cemborain A, Castilla-Cortázar I, Garcia M, Quiroga J, Muguerza B, Picardi A. Osteopenia in rats with liver cirrhosis: benefical effects of IGF-I treatment. J Hepatol 1998; 28: 122-131.
33. Ruiz-Gaspà S, Guañabens N, Enjuanes A, Peris P, Martinez-Ferrer A, de Osaba MJ. Lithocolic acid downregulates vitamin D effects in human osteoblasts. Eur J Clin Invest 2010; 40: 25-34.
34. McCaughan GW, Feller RB. Osteoporosis in chronic liver disease: pathogenesis, risk factors and management. Dig Dis 1994; 12: 223-231.
35. Gasser RW. Cholestasis and metabolic bone disease - a clinical review. Wien Med Wochenschr 2008; 158: 553-557.
36. Angulo P, Grandison GA, Fong DG etal. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 2011; 140: 180-188.
37. Ninkovic M, Love SA, Tom B, Alexander GJ, Compston JE. High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int 2001; 69: 321-326.
38. Choudhary NS, Tomar M, Chawla YK etal. Hepatic osteodystrophy is common in patients with noncholestatic liver disease. Dig Dis Sci 2011; 56: 3323-3327.
39. Collier J. Bone disorders in chronic liver disease. Hepatology 2007; 46: 1271-1278.
40. Bode C, Bode JC. Effect of alcohol consumption on the gut. Best Pract Res Clin Gastroenterol 2003; 4: 575-592.
41. Cheung K, Lee SS, Raman N. Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clin Gastroenterol Hepatol 2012; 2: 117-125.
42. Campos AC, Matias JE, Coelho JC. Nutritional aspects of liver transplantation. Curr Opin Clin Nutr Metab Care 2002; 5: 297-307.
43. Sarfeh IJ, Aaronson S, Lombino D etal. Selective impairment of nutrient absorption from intestines with chronic venous hypertension. Surgery 1986; 2 (99): 166-169.
44. Szalay F, Folhoffer A, Horvath A. Serum leptin, soluble leptin receptor, free leptin index and bone mineral density in patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2005; 17: 923-928.
45. Verschueren S, Gielen E, O'Neill TW etal. Sarcopenia and its relationship with bone mineral density in middle-aged and elderly European men. Osteoporos Int 2013; 1 (24): 87-98.
46. Orsatti FL, Nahas EA, Nahas-Neto J etal. Low appendicular muscle mass is correlated with femoral neck bone mineral density bone loss in postmenopausal women. BMC Musculoeskelet Disord 2011; 12: 225.
47. Cabré E, Gonzalez-Huix F, Abad-Lacruz A etal. Effect of total enteral nutrition on the short term outcome of severely malnourished cirrhotics. A randomized controlled trial. Gastroenterology 1990; 98: 715-720.
48. Kearns PJ, Young H, Garcia G etal. Accelerated improvement of alcoholic liver disease with enteral nutrition. Gastroenterology 1992; 102 (1): 200-205.
49. González-Madroño A, Mancha A, Rodríguez FJ, Culebras J, de Ulíbarri JI. Confirming the validity of the CONUT system for early detection and monitoring of clinical undernutrition; comparison with two logistic regression models developed using SGA as the gold standard. Nutr Hosp 2012; 2: 564-571.
50. Fukushima K, Ueno Y, Kawagishi N etal. The nutritional index CONUT is useful for predicting long-term prognosis of patients with end-stage liver diseases. Tohoku J Exp Med 2011; 3 (224): 215-219.
51. Lautz HU, Selberg O, Körber J, Bürger M, Müller MJ. Protein-calorie malnutrition in liver cirrhosis. Clin Investig 1992; 6: 478-486.
52. Caregaro L, Alberino F, Amodio P etal. Malnutrition in alcoholic and virus-related cirrhosis. Am J Clin Nutr 1996; 63: 602-609.
53. Kawabe N, Hashimoto S, Harata M etal. Assessment of nutritional status of patients with hepatitis C virus-related liver cirrhosis. Hepatol Res 2008; 38: 484-490.
54. Crawford DH, Shepherd RW, Halliday JW etal. Body composition in nonalcoholic cirrhosis: the effect of disease etiology and severity on nutritional compartments. Gastroenterology 1994; 106: 1611-1617.
55. DiCecco SR, Wieners EJ, Wiesner RH, Southorn PA, Plevak DJ, Krom RA. Assessment of nutritional status of patients with end-stage liver disease undergoing liver transplantation. Mayo Clin Proc 1989; 64: 95-102.
56. López-Larramona G, Lucendo AJ, González-Castillo S, Tenias JM. Hepatic osteodystrophy: an important matter for consideration in chronic liver disease. World J Hepatol 2011; 3: 300-307.
57. Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc 2002; 77: 453-468.
58. Carey E, Balan V. Metabolic bone disease in patients with liver disease. Curr Gastroenterol Rep 2003; 5 (1): 71-77.
59. Brodeur MR, Brissette L, Falstrault L, Moreau R. HDL3 reduces the association and modulates the metabolism of oxidized LDL by osteoblastic cells: a protection against cell death. J Cell Biochem 2008; 105: 1374-1385.
60. Luegmayr E, Glantschnig H, Wesolowsky GA etal. Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins. Cell Death Differ 2004; 11 (Suppl): S108-118.
61. Ackert-Bicknell CL. HDL cholesterol and bone mineral density: is there a genetic link? Bone 2012; 50: 525-533.
62. Schilling AF, Schinke T, Munch C etal. Increased bone formation in mice lacking apolipoprotein E. J Bone Miner Res 2005; 20: 274-282.
63. Pelton K, Krieder J, Joiner D, Freeman MR, Goldstein SA, Solomon KR. Hypercholesterolemia promotes an osteoporotic phenotype. Am J Pathol 2012; 181: 928-936.
64. Graham LS, Parhami F, Tintut Y, Kitchen CMR, Demer LL, Effros RB. Oxidized lipids enhance RANKL production by T lymphocites: implications for lipid-induced bone loss. Clin Immunol 2009; 133: 265-275.
65. Graham LS, Tintut Y, Parhami F etal. Bone density and hyperlipidemia: the T-lymphocite connection. J Bone Miner Res 2010; 25: 2460-2469.
66. Sarkis KS, Martini LA, Szejnfeld VL, Pinheiro MM. Low fatness, reduced fat intake and adequate plasmatic concentrations of LDL-cholesterol are associated with high bone mineral density in women: a cross-sectional study with control group. Lipids Health Dis 2012; 11: 37.
67. Tarakida A, Iino K, Abe K etal. Hypercholesterolemia accelerates bone loss in postmenopausal women. Climacteric 2011; 1: 105-111.
68. Majima T, Shimatsu A, Komatsu Y etal. Increased bone turnover in patients with hypercholesterolemia. Endocr J 2008; 1 (55): 143-151.
69. Samelson EJ, Cupples LA, Hannan MT etal. Long-term effects of serum cholesterol on bone mineral density in women and men: the Framingham Osteoporosis Study. Bone 2004; 34: 557-561.
70. Go JH, Song YM, Park JH, Park JY, Choi YH. Association between serum cholesterol level and bone mineral density at lumbar spine and femur neck in postmenopausal Korean women. Korean J Fam Med 2012; 33: 166-173.
71. Tanko LB, Bagger YZ, Nielsen SB, Christiansen C. Does serum cholesterol contribute to vertebral bone loss in postmenopausal women? Bone 2003; 32: 8-14.